Patents by Inventor Gisbert Schneider

Gisbert Schneider has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SMALL-MOLECULE INHIBITORS OF THE FRS2-FGFR INTERACTION AND THEIR USE IN MEDICINE, IN THE PREVENTION AND TREATMENT OF CANCER
    Publication number: 20230212126
    Abstract: The present invention relates to small-molecule inhibitors of the FRS2-FGFR interaction. The present invention relates the small-molecule inhibitors for use as a medicament and for use in cancer or metastasis treatment or prevention.
    Type: Application
    Filed: June 8, 2021
    Publication date: July 6, 2023
    Applicants: UNIVERSITÄT ZÜRICH, ETH ZÜRICH
    Inventors: Gisbert SCHNEIDER, Cyrill BRUNNER, Martin BAUMGARTNER, Karthiga Santhana KUMAR, Oliver ZERBE
  • SMALL-MOLECULE INHIBITORS OF THE FRS2-FGFR INTERACTION
    Publication number: 20230212124
    Abstract: The present invention relates to small-molecule inhibitors of the FRS2-FGFR interaction. The present invention relates the small-molecule inhibitors for use as a medicament and for use in cancer treatment or prevention.
    Type: Application
    Filed: June 8, 2021
    Publication date: July 6, 2023
    Applicants: UNIVERSITÄT ZÜRICH, ETH ZÜRICH
    Inventors: Gisbert SCHNEIDER, Cyrill BRUNNER, Martin BAUMGARTNER, Karthiga Santhana KUMAR, Oliver ZERBE
  • NEW COMPOUNDS FOR USE AS A THERAPEUTICALLY ACTIVE SUBSTANCE AND IN PARTICULAR FOR USE IN THE TREATMENT OF TUMORS
    Publication number: 20210179591
    Abstract: The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 is selected from fluoro, methoxy and ethoxy, each R2 is independently selected from hydrogen, fluorine and methyl, n is O, 1, 2, 3, 4 or 5, R3 is selected from hydrogen, fluorine, amino, hydroxy, and a five or six membered substituted or unsubstituted ring system which may be aromatic or aliphatic, comprising 1 or 2 heteroatoms selected from the group consisting of nitrogen and oxygen, R4 is hydrogen or methyl, for use as a therapeutically active substance.
    Type: Application
    Filed: December 5, 2018
    Publication date: June 17, 2021
    Inventors: Blaise CALPE, Wilhelm KREK, Gisbert SCHNEIDER, Petra SCHNEIDER
  • SMALL MOLECULE LFA-1 INHIBITORS
    Publication number: 20190040008
    Abstract: The present invention relates to novel compounds which are capable of inhibiting the interaction of LFA-1 with its counter ligands.
    Type: Application
    Filed: August 2, 2018
    Publication date: February 7, 2019
    Applicant: ALLOCYTE PHARMACEUTICALS AG
    Inventors: Werner BREITENSTEIN, Marianne HUERZELER, Terence KELLY, Riccardo MANCUSO, Gisbert SCHNEIDER, Gabriele WEITZ-SCHMIDT
  • Small molecule LFA-1 inhibitors
    Patent number: 10077238
    Abstract: The present invention relates to novel compounds which are capable of inhibiting the interaction of LFA-1 with its counter ligands.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: September 18, 2018
    Assignee: ALLOCYTE PHARMACEUTICALS AG
    Inventors: Werner Breitenstein, Marianne Huerzeler, Terence Kelly, Riccardo Mancuso, Gisbert Schneider, Gabriele Weitz-Schmidt
  • Pharmaceutical compounds for use in the therapy of clostridium difficile infection
    Patent number: 9751903
    Abstract: The invention relates to a compound described by a general formula (1), wherein each X independently from other X can be OPO32?, OPSO22? or OSO3?; R1 is a solubility function such as a polyethylene glycol moiety. The invention further relates to the use of the compounds according to the invention in the therapy of infection by Clostridium difficile.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: September 5, 2017
    Assignee: ETH ZURICH
    Inventors: Bastien Castagner, Jean-Christophe Leroux, Mattias Ivarsson, Gisbert Schneider, Anna Pratsinis
  • SMALL MOLECULE LFA-1 INHIBITORS
    Publication number: 20170121284
    Abstract: The present invention relates to novel compounds which are capable of inhibiting the interaction of LFA-1 with its counter ligands.
    Type: Application
    Filed: June 10, 2015
    Publication date: May 4, 2017
    Applicant: ALLOCYTE PHARMACEUTICALS AG
    Inventors: Werner BREITENSTEIN, Marianne HUERZELER, Terence KELLY, Riccardo MANCUSO, Gisbert SCHNEIDER, Gabriele WEITZ-SCHMIDT
  • PHARMACEUTICAL COMPOUNDS FOR USE IN THE THERAPY OF CLOSTRIDIUM DIFFICILE INFECTION
    Publication number: 20160280727
    Abstract: The invention relates to a compound described by a general formula (1), wherein each X independently from other X can be OPO32?, OPSO22? or OSO3?; R1 is a solubility function such as a polyethylene glycol moiety. The invention further relates to the use of the compounds according to the invention in the therapy of infection by Clostridium difficile.
    Type: Application
    Filed: June 3, 2016
    Publication date: September 29, 2016
    Applicant: ETH Zurich
    Inventors: Bastien CASTAGNER, Jean-Christophe LEROUX, Mattias IVARSSON, Gisbert SCHNEIDER, Anna PRATSINIS
  • Pharmaceutical compounds for use in the therapy of infection
    Patent number: 9358243
    Abstract: The invention relates to a compound described by a general formula (1), wherein each X independently can be OPO32?, OPSO22? or OSO3?; R1 comprises a solubility function such as a polyethylene glycol moiety and each X independently can be OPO32?, OPSO22?, ? or OSO3?; and Z is an alkyl chain comprising 1 to 3 carbon and/or hetero atoms. The invention further relates to polysulfate derivatives or mixed polyphosphate/sulphate derivatives of six-membered cyclic polyols for use in the therapy of infection by Clostridium difficile.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: June 7, 2016
    Assignee: ETH ZURICH
    Inventors: Bastien Castagner, Jean-Christophe Leroux, Mattias Ivarsson, Gisbert Schneider, Anna Pratsinis
  • PHARMACEUTICAL COMPOUNDS FOR USE IN THE THERAPY OF CLOSTRIDIUM DIFFICILE INFECTION
    Publication number: 20140235590
    Abstract: The invention relates to a compound described by a general formula (1), wherein each X independently can be OPO32?, OPSO22? or OSO3?; R1 comprises a solubility function such as a polyethylene glycol moiety and each X independently can be OPO32?, OPSO22?, ? or OSO3?; and Z is an alkyl chain comprising 1 to 3 carbon and/or hetero atoms. The invention further relates to polysulfate derivatives or mixed polyphosphate/sulphate derivatives of six-membered cyclic polyols for use in the therapy of infection by Clostridium difficile.
    Type: Application
    Filed: September 28, 2012
    Publication date: August 21, 2014
    Applicant: ETH ZURICH
    Inventors: Bastien Castagner, Jean-Christophe Leroux, Mattias Ivarsson, Gisbert Schneider, Anna Pratsinis
  • Benzodioxole derivatives
    Patent number: 7576088
    Abstract: The present invention relates to compounds of the general formula and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases such as obesity by selective modulation of CB1 receptors.
    Type: Grant
    Filed: February 22, 2005
    Date of Patent: August 18, 2009
    Assignee: Hoffman-La Roche Inc.
    Inventors: Alexander Alanine, Konrad Bleicher, Wolfgang Guba, Wolfgang Haap, Dagmar Kube, Thomas Luebbers, Jean-Marc Plancher, Olivier Roche, Mark Rogers-Evans, Gisbert Schneider, Jochen Zuegge
  • Benzodioxole derivatives
    Publication number: 20050143373
    Abstract: The present invention relates to compounds of the general formula and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases such as obesity by selective modulation of CB1 receptors.
    Type: Application
    Filed: February 22, 2005
    Publication date: June 30, 2005
    Inventors: Alexander Alanine, Konrad Bleicher, Wolfgang Guba, Wolfgang Haap, Dagmar Kube, Thomas Luebbers, Jean-Marc Plancher, Olivier Roche, Mark Rogers-Evans, Gisbert Schneider, Jochen Zuegge
  • Benzodioxole derivatives
    Patent number: 6900227
    Abstract: The present invention relates to compounds of the general formula and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases such as obesity by selective modulation of CB1 receptors.
    Type: Grant
    Filed: July 24, 2003
    Date of Patent: May 31, 2005
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Alexander Alanine, Konrad Bleicher, Wolfgang Guba, Wolfgang Haap, Dagmar Kube, Thomas Luebbers, Jean-Marc Plancher, Olivier Roche, Mark Rogers-Evans, Gisbert Schneider, Jochen Zuegge
  • Benzodioxole derivatives
    Publication number: 20040142922
    Abstract: The present invention relates to compounds of the general formula 1
    Type: Application
    Filed: July 24, 2003
    Publication date: July 22, 2004
    Inventors: Alexander Alanine, Konrad Bleicher, Wolfgang Guba, Wolfgang Haap, Dagmar Kube, Thomas Luebbers, Jean-Marc Plancher, Olivier Roche, Mark Rogers-Evans, Gisbert Schneider, Jochen Zuegge